The history of cord blood banking is fascinating, because the service did not exist on a widespread basis until a few decades ago. Below, we introduce key historical events that have affected cord blood and cord tissue storage, both in the U.S. and worldwide.
[Read more…]
Celularity announces multi-year research collaboration services agreement with Regeneron
In major news that broke this morning, Celularity (CELU) has announced a partnership with Regeneron (REGN) to support the research, preclinical development, and manufacturing of allogeneic targeted cell therapy candidates targeting difficult-to-treat cancers.
The selection follows months of rigorous assessment and due diligence by Regeneron and showcases a high level of confidence and validation of Celularity’s core science, business model, and strategic vision. Celularity’s expertise in the off-the-shelf allogeneic cell therapy field is exceptional and includes the engineering and design of chimeric antigen receptors (CAR) for use with T and natural Killer (NK) cells. [Read more…]
PeptiGrowth Inc. and Orizuru Therapeutics, Inc. Enter into Joint Development of Novel Synthetic Peptide Based Growth Factor
TOKYO and KANAGAWA, JAPAN –  PeptiGrowth Inc (PeptiGrowth), a Japanese biotechnology company focusing on the development of synthetic peptide based growth factors and Orizuru Therapeutics, Inc(OZTx), a Japanese biopharmaceutical company focusing on the research and development of iPSC-derived regenerative medicine have entered into a joint development agreement to create a novel synthetic peptide that will replace a recombinant growth factor used in the manufacturing of regenerative medicine product developed by OZTx. [Read more…]
Qrons Announces Launch of its New Website in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis
NEW YORK, NY – Qrons Inc. (OTCQB:QRON) an innovative biotechnology company dedicated to developing products treatments and technologies to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria, announced today the launch of its updated website at www.qrons.com. This update will provide investors and the public an overview of the company’s strides in dealing with infectious disease and sepsis with a focus on antibiotic resistant bacteria, which is becoming the most prominent and rapidly growing worldwide cause of illness and death. This is in addition to the Company’s combatting traumatic brain injuries and other neuronal diseases. [Read more…]
Aspen Neuroscience Secures an for IND for ANPD001, a Novel Cell Therapy for Parkinson’s Disease
Aspen Neuroscience, a pioneering force in regenerative medicine, has received clearance from the U.S. FDA for its Investigational New Drug (IND) application for ANPD001. ANPD001 is a novel autologous (“self-derived”) cell therapy that has the potential to treat Parkinson’s Disease by replenishing lost dopamine neurons. This green light from the FDA propels Aspen Neuroscience into historic territory, initiating a clinical trial for ANPD001 in human patients. [Read more…]
- « Previous Page
- 1
- …
- 112
- 113
- 114
- 115
- 116
- …
- 334
- Next Page »